I am no stats professor but I believe the DMX200 vs placebo reduction should be 2%, not 12%. This is the problematic area - the part where the legacy effect argument lies.
I thought the average 14% reduction for DMX200 vs baseline is very close to statistical significance (15%) but this is not observed in DMX200 vs placebo. I saw a post where one postulates that it is easy to plot this out and conclude whether there is any legacy effect or not - I don't think it is that simple and straightforward - Even if the graph visually tells you there is a correlation, it is not necessarily a legacy effect (cause) from DMX 200. I believe they will need to review medication, diet, etc.. before jumping to a conclusion. So, I thought they are being careful not to mislead the market unless they are fairly certain (not just by looking at numbers alone).
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-344
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 26318 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 170072 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1318 | 0.380 |
3 | 72579 | 0.375 |
4 | 134161 | 0.370 |
1 | 30000 | 0.365 |
4 | 27499 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 140963 | 5 |
0.395 | 61740 | 2 |
0.400 | 115000 | 2 |
0.405 | 86528 | 4 |
0.410 | 56400 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |